Pfizer's combo cholesterol drug draws fire

A Harvard University researcher is urging Pfizer to split its cholesterol drugs to allow patients a better shot at improving their health. Pfizer has been under attack for considering a plan to market its new drug torcetrapib for lowering LDL, or bad cholesterol, in combination with Lipitor, which raises HDL, or good cholesterol. A number of researchers, though, say the drugs should be sold separately to provide patients with greater choices. Pfizer has been accused of proposing a combination because its patent for Lipitor will expire in 2010. Analysts say a combination pill could be worth up to $15 billion per year for Pfizer.

- read this story from the Los Angeles Times for more

ALSO: Pfizer is planning to outsource some of its IT work to India as part of a cost-saving plan. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.